K
Koichi Hagiwara
Researcher at Jichi Medical University
Publications - 213
Citations - 14104
Koichi Hagiwara is an academic researcher from Jichi Medical University. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 42, co-authored 203 publications receiving 12308 citations. Previous affiliations of Koichi Hagiwara include Saitama Medical University.
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
Mutations of optineurin in amyotrophic lateral sclerosis
Hirofumi Maruyama,Hiroyuki Morino,Hidefumi Ito,Hidefumi Ito,Yuishin Izumi,Hidemasa Kato,Yasuhito Watanabe,Yoshimi Kinoshita,Masaki Kamada,Masaki Kamada,Hiroyuki Nodera,Hidenori Suzuki,Osamu Komure,Shinya Matsuura,Keitaro Kobatake,Nobutoshi Morimoto,Koji Abe,Naoki Suzuki,Masashi Aoki,Akihiro Kawata,Takeshi Hirai,Takeo Kato,Kazumasa Ogasawara,Asao Hirano,Toru Takumi,Hirofumi Kusaka,Koichi Hagiwara,Ryuji Kaji,Hideshi Kawakami +28 more
TL;DR: It is shown that there are mutations in the gene encoding optineurin (OPTN), earlier reported to be a causative gene of primary open-angle glaucoma (POAG), in patients with ALS and these findings strongly suggest that OPTN is involved in the pathogenesis of ALS.
Journal ArticleDOI
Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp
Yoshiaki Nagai,Hitoshi Miyazawa,Huqun,Tomoaki Tanaka,Kiyoshi Udagawa,Motoyasu Kato,Shunichiro Fukuyama,Akemi Yokote,Kunihiko Kobayashi,Minoru Kanazawa,Koichi Hagiwara +10 more
TL;DR: Genetic heterogeneity of EGFR suggests that the EGFR gene is unstable in established cancers and the heterogeneity may explain variable clinical responses of lung cancers to gefitinib.
Journal ArticleDOI
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
Akira Inoue,Kazuhiko Kobayashi,Makoto Maemondo,Shunichi Sugawara,Satoshi Oizumi,Hiroaki Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,H. Hirano,Kozo Yoshimori,Toshiyuki Harada,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +18 more
TL;DR: Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended.
Journal ArticleDOI
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue,Kunihiko Kobayashi,Kazuhiro Usui,Makoto Maemondo,Shoji Okinaga,Iwao Mikami,Masahiro Ando,Koichi Yamazaki,Yasuo Saijo,Akihiko Gemma,Hitoshi Miyazawa,Tomoaki Tanaka,Kenji Ikebuchi,Toshihiro Nukiwa,Satoshi Morita,Koichi Hagiwara +15 more
TL;DR: This is the first report indicating that EGFR mutation-positive patients with extremely poor PS benefit from first-line gefitinib, and examination of EGFR mutations as a biomarker is recommended in this patient population.